Dermata Therapeutics (DRMA) Q2 2026 earnings summary

Executive summary

• Strategic pivot completed in September 2025 to become a direct-to-consumer skincare company, with the first product, Tome Foundational Treatment, launching August 25, 2026.

• No revenue generated to date; focus on commercialization, marketing, and brand awareness initiatives, including trade shows and social media campaigns.

• Ongoing litigation with Villani, Inc. regarding Spongilla-based products, with recent court decisions favoring the company but litigation unresolved.

Financial highlights

• Net loss for Q2 2026 was $2.97 million, compared to $1.70 million in Q2 2025; net loss for the six months ended June 30, 2026, was $4.81 million versus $4.00 million in the prior year.

• Operating expenses increased to $3.01 million in Q2 2026 from $1.77 million in Q2 2025, driven by higher marketing, legal, and commercialization costs.

• Cash and cash equivalents were $4.4 million as of June 30, 2026, down from $7.5 million at year-end 2025.

• Research and development expenses decreased to $0.2 million in Q2 2026 from $0.6 million in Q2 2025.

• Selling, general, and administrative expenses rose to $2.8 million in Q2 2026 from $1.2 million in Q2 2025.

Outlook and guidance

• Cash runway expected to fund operations into Q4 2026; additional capital will be needed beyond that point.

• Anticipates generating revenue with the launch of Tome Foundational Treatment in August 2026; second OTC acne treatment in development.

• Focus remains on successful launch, commercialization, and expansion of the product portfolio.